Moderna in the news

Moderna's stock is rising due to positive cancer vaccine trial results and a diversified respiratory portfolio, despite financial risks.

Moderna's cancer vaccine, intismeran, showed positive Phase III results in melanoma, bolstering its T-cell-priming strategy and prompting further trials across various tumor types.

Moderna (MRNA) is rated a Sell due to overvaluation post-melanoma trial news, with its current price ignoring significant risks, while the MRNY ETF is also a Sell due to limited downside protection.

Moderna's stock saw a notable gain in the recent trading session and a significant increase over the past month, while upcoming earnings anticipate a decrease in EPS and revenue compared to the prior year.

Analysts show mixed views on Moderna stock amid declining revenue but strong net margin and low debt.

UBS downgraded Moderna to neutral and cut its price target to $34 due to concerns about flat revenue growth and profitability challenges.

Moderna's stock rallied ahead of a healthcare conference, driven by recent product approvals, expected cancer vaccine trial data in 2026, and investor optimism despite mixed analyst views.

BofA increased Moderna's price target to $24 while maintaining an underperform rating, noting its diverse clinical pipeline and strong US sales.

Moderna's stock is climbing due to renewed investor interest amid strong execution and pipeline progress despite expected 2025 challenges.

BofA raised Moderna's price target to $24 citing cost cuts and pipeline potential but kept an Underperform rating amid cash burn and COVID-19 vaccine market uncertainties.

Moderna's stock has modestly rebounded but remains undervalued amid pipeline expansion beyond COVID-19 vaccines and risks from competition and demand erosion.

Moderna projects steady Covid vaccine sales through 2025 and plans to expand its mRNA vaccine pipeline into oncology and rare diseases by 2028.

Moderna issued a shareholder letter amid financial challenges, received EMA recommendation for a new COVID-19 vaccine, and faces FDA investigation on vaccine safety.

Moderna expanded its product portfolio, manufacturing footprint, and pipeline in 2025 while maintaining financial discipline.

Moderna seeks approval for its mRNA flu vaccine targeting older adults to drive future growth amid recent setbacks.

Moderna has applied for approval of its mRNA-based seasonal flu vaccine, aiming to expand its mRNA technology beyond COVID-19.

Moderna has submitted its flu vaccine for global regulatory approval amid other pharmaceutical updates.

Moderna has filed for global regulatory approval of its seasonal flu vaccine mRNA-1010 for adults over 50.

Moderna has filed for approval of its mRNA-based seasonal flu vaccine mRNA-1010, showing superior efficacy and safety in adults 50+, aiming for market entry in multiple countries.

Moderna's stock surged after receiving $54.3 million from CEPI to fund a pivotal Phase 3 trial for its mRNA-based bird flu vaccine, marking a key step toward potential approval.